The Gill Center and the Department of Psychological & Brain Sciences, Indiana University, Bloomington, IN 47405, USA.
Br J Pharmacol. 2010 Jun;160(3):467-79. doi: 10.1111/j.1476-5381.2010.00729.x.
CB(2) was first considered to be the 'peripheral cannabinoid receptor'. This title was bestowed based on its abundant expression in the immune system and presumed absence from the central nervous system. However, multiple recent reports question the absence of CB(2) from the central nervous system. For example, it is now well accepted that CB(2) is expressed in brain microglia during neuroinflammation. However, the extent of CB(2) expression in neurons has remained controversial. There have been studies claiming either extreme-its complete absence to its widespread expression-as well as everything in between. This review will discuss the reported tissue distribution of CB(2) with a focus on CB(2) in neurons, particularly those in the central nervous system as well as the implications of that presence. As CB(2) is an attractive therapeutic target for pain management and immune system modulation without overt psychoactivity, defining the extent of its presence in neurons will have a significant impact on drug discovery. Our recommendation is to encourage cautious interpretation of data that have been presented for and against CB(2)'s presence in neurons and to encourage continued rigorous study.
CB(2) 最初被认为是“外周大麻素受体”。这个名称是基于其在免疫系统中的丰富表达和推测在中枢神经系统中的不存在而赋予的。然而,最近的多项报告质疑 CB(2) 是否存在于中枢神经系统中。例如,现在人们普遍认为,CB(2) 在神经炎症期间表达于脑小胶质细胞中。然而,神经元中 CB(2) 的表达程度一直存在争议。有研究声称,其存在范围从完全不存在到广泛表达,甚至介于两者之间。本综述将讨论报告的 CB(2) 组织分布情况,重点是神经元中的 CB(2),特别是中枢神经系统中的神经元,以及其存在的意义。由于 CB(2) 是一种具有吸引力的治疗靶点,可用于管理疼痛和调节免疫系统而没有明显的精神活性,因此确定其在神经元中的存在程度将对药物发现产生重大影响。我们的建议是,鼓励谨慎解释支持和反对 CB(2) 在神经元中存在的数据,并鼓励继续进行严格的研究。